Klivira
Request demo

Streamlining Medicare Tremfya Prior Authorization

Efficiently managing **Medicare Tremfya prior authorization** requires a nuanced understanding of both Original Medicare and Medicare Advantage plan requirements.

For revenue cycle directors and prior authorization coordinators, securing approvals for high-cost biologics like Tremfya under Medicare presents unique challenges. This includes navigating distinct processes for Traditional Medicare's limited PA scope and the broader requirements of Medicare Advantage and Part D plans.

Understanding Tremfya's Role in Medicare Coverage

Tremfya (guselkumab) is a biologic medication indicated for conditions such as moderate to severe plaque psoriasis and active psoriatic arthritis. As a high-cost specialty drug, it frequently triggers prior authorization requirements across various payer types, including Medicare. For Medicare beneficiaries, coverage and PA requirements are determined by whether the patient is enrolled in Original Medicare (Parts A/B) or a Medicare Advantage (Part C) plan, which often includes Part D prescription drug coverage.

Navigating Prior Authorization for Tremfya in Original Medicare

Under Original Medicare, prior authorization for medical services, including those related to the administration of infusible biologics (if applicable), is generally limited. Where PA does apply, such as for specific outpatient department services or durable medical equipment (DME), submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira's platform supports MAC-aware routing, connecting to contractors like Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Medicare Part D and Medicare Advantage Plans: Tremfya PA Specifics

Medicare Part D plans, operated by private insurers, administer pharmacy prior authorization for self-administered medications like Tremfya. These plans follow CMS-approved formularies and step-therapy protocols. Medicare Advantage (MA) plans (Part C) often integrate medical and pharmacy benefits, leading to expanded prior authorization requirements compared to Original Medicare. Specific formulary tiers, step-therapy prerequisites, and quantity limits for Tremfya will vary significantly by individual MA and Part D plan.

Key Considerations for Tremfya Prior Authorization Under Medicare

  • **MAC Jurisdiction:** Identify the correct Medicare Administrative Contractor (MAC) for medical benefit PAs under Original Medicare, leveraging Klivira's MAC-aware routing.
  • **Policy Adherence:** Reference National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) published by CMS and MACs, respectively, for medical necessity criteria.
  • **Part D Formularies:** Understand the specific formulary and step-therapy requirements of the patient's Part D or Medicare Advantage plan for pharmacy benefit PAs.
  • **Documentation:** Ensure comprehensive clinical documentation supporting the diagnosis, prior therapies, and medical necessity per payer policy.
  • **Turnaround Times:** Be aware of specific turnaround timeframes for Medicare PA programs, noting that CMS-0057-F primarily impacts MA plans, not Traditional Medicare.

Optimizing Tremfya Prior Authorization Workflows with Klivira

Klivira automates the submission process for Tremfya prior authorizations, adapting to the distinct requirements of Medicare. For Original Medicare's limited PA scope, our platform facilitates compliant submissions via MAC-jurisdiction channels with NCD/LCD-aware policy logic. For Medicare Advantage and Part D plans, Klivira streamlines the ePA process by integrating with payer portals and leveraging digital submission standards, helping to manage the expanded PA requirements.

Frequently asked questions

How does prior authorization for Tremfya differ between Original Medicare and Medicare Advantage plans?

Original Medicare has a limited scope for prior authorization, primarily for specific medical services, and routes through MACs. Medicare Advantage plans, which are private plans, typically have broader prior authorization requirements for both medical and pharmacy benefits, including for specialty drugs like Tremfya, often aligning with commercial plan structures.

Which Medicare Administrative Contractors (MACs) handle Tremfya-related prior authorizations?

For medical services under Original Medicare where prior authorization applies, submissions are routed through the MAC responsible for the provider's jurisdiction. This includes contractors such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas. Klivira's system is configured to route to the appropriate MAC.

Are there specific National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs) for Tremfya under Medicare?

While general NCDs and MAC-specific LCDs exist for various medical services and conditions, specific policy details for drugs like Tremfya are often found within the formularies and utilization management criteria of individual Medicare Part D or Medicare Advantage plans. Providers should consult the relevant NCDs, LCDs, and plan policies.

How does Klivira assist with Tremfya prior authorizations for Medicare Part D plans?

Klivira integrates with the submission channels used by Medicare Part D plans, which are operated by commercial insurers. Our platform helps automate the electronic prior authorization (ePA) process, adhering to CMS-approved formularies and step-therapy protocols, and reducing manual effort for your team.

What are common reasons for Tremfya prior authorization denials under Medicare?

Common denial reasons for specialty drugs like Tremfya under Medicare Part D or Medicare Advantage plans often include failure to meet step-therapy requirements, insufficient documentation of medical necessity, lack of previous failed therapies, or non-adherence to specific plan-level criteria. Appeals processes are defined by each plan and typically involve submitting additional clinical information.

Related coverage

Other tremfya prior authorization by payer

Other tremfya prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo